Clinical trials: Unresectable
Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
TROPION Breast Respond in 1L TNBC
There are no real-world data available on the effectiveness and safety of Dato-DXd in adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.
- Trial name
- NCT07867470
- Testing
- Dato-DXd
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Perihilar Cholangiocarcinoma, Klatskin Tumor
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using…
- Trial name
- pCOLA (NCT06986486)
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pancreatic Cancer
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally…
- Trial name
- NCT06313970
- Testing
- QL1706, Nab-paclitaxel, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Liver Metastasis
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor
The purpose of this study is to see if treatment with intrahepatic chemotherapy is a good options in patients with liver metastases.
- Trial name
- NCT01511146
- Testing
- Oxaliplatin, Mitomycin + Gemcitabine
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital at Herlev
Colorectal Cancer, Liver Metastases
Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis
For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving effective conversion therapy, disease relapse after conversion hepatectomy is common due to the extensive tumor load.
- Trial name
- NCT05462470
- Testing
- Repeat Liver Surgery, Non-Repeat Liver Surgery
- Volunteers
- 255 people
- Sponsor
- Fudan University
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the…
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT05176223
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Unresectable Solid Tumor, Metastatic Cancer
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys"…
- Trial name
- NCT05831579
- Testing
- Proton GRID Radiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes…
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1
- Trial name
- NCT03375320
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 432 sites in United States
- Volunteers
- 298 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Soft Tissue Sarcoma
Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma
The goal of this study is to find the highest tolerated dose of NC-6300 that can be given to patients with advanced solid tumors or soft tissue sarcoma. The safety and tolerability of the drug will also be studied.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Metastatic Sarcoma, Sarcoma
- Trial name
- NCT03168061
- Testing
- NC 6300
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- NanoCarrier Co., Ltd.
Lung Cancer, Head and Neck Cancer
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
- Conditions
- Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer
- Trial name
- NCT04316689
- Testing
- S-488210, S-488211
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Shionogi
Unresectable Hepatocellular Carcinoma
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC.
- Trial name
- NCT06896396
- Testing
- Lenvatinib, Pembrolizumab, Icaritin soft capsules, TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhiyong Huang
Stage III or IV Melanoma
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment in Stage III or IV melanoma. Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control rates.
- Trial name
- NCT02200562
- Testing
- ipilimumab and dabrafenib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Utah
Lung Metastases, Endobronchial Metastases
Chemoembolization for Lung Tumors
This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
- Conditions
- Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
- Trial name
- NCT04200417
- Testing
- Chemoembolization, Mitomycin C, Lipiodol
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine)…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT06998940
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- 274 sites in United States
- Volunteers
- 94 people
- Sponsor
- SWOG Cancer Research Network
HER2 Gene Mutation
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
The study aims to evaluate the efficacy and safety of IAH0968 in combination with gemcitabine and cisplatin for the treatment of HER2-positive unresectable advanced/metastatic malignant tumors and cholangiocarcinoma.
- Trial name
- NCT05991518
- Testing
- Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin
- Where
- China
- Volunteers
- 136 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Adenocarcinoma of the Pancreas, Locally Advanced
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
This study is a phase 2, multicenter, randomized, double-blind, active placebo-controlled trial of AMG 479 or placebo in combination with gemcitabine as first-line therapy for locally advanced unresectable adenocarinoma of the…
- Conditions
- Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable
- Trial name
- NCT01318642
- Testing
- Gemcitabine, AMG 479
- Where
- 35 sites in United States, Austria and 11 more
- Volunteers
- 10 people
- Sponsor
- NantBioScience, Inc.
Lung Cancer
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy…
- Trial name
- NCT00226590
- Testing
- Gemcitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.